Summary:We describe an infant with severe combined immunodeficiency syndrome and an ␣-thalassemia trait who developed a renal Fanconi syndrome after his first stem cell transplantation. This syndrome consists of a generalized failure of proximal tubular reabsorption, which leads to a large number of metabolic disturbances. The etiology varies from inherited causes, including an idiopathic form, to acquired causes such as intoxications, immunological disorders and hemoglobinopathies. In this case report we discuss possible explanations of the Fanconi syndrome in our patient. Bone Marrow Transplantation (2000) 26, 97-99. Keywords: immunodeficiency; ␣-thalassemia; bone marrow transplantation; Fanconi syndromeThe de Toni-Debré-Fanconi syndrome is characterized by a general dysfunction of the proximal tubule, leading to an excessive urinary loss of amino acids, glucose, bicarbonate, phosphate and other solutes normally absorbed in the proximal tubule. The consequences of these losses are hyperchloremic metabolic acidosis, decreased plasma phosphate levels, electrolyte imbalance, which can lead to severe dehydration, rickets, and growth retardation. The syndrome was first described by Lignac in 1924.1 In 1943, McCune et al 2 abbreviated the name to Fanconi syndrome. We describe a boy with severe combined immunodeficiency syndrome (SCID), ␣ 0 -thalassemia and Fanconi syndrome, a combination of rare diseases not previously reported.
Case reportA 1-month-old Turkish boy, born 20 March 1998, was admitted to our hospital in April 1998 for a cord blood transplantation from a matched unrelated donor for his RAG-2 point mutation (deletion of a guanin nucleotide at position 1913, which causes a frame shift and a stop codon at amino acid position 247) autosomal recessive SCID (non T, non B). He was born after an uneventful pregnancy and delivery from consanguineous parents (first cousins), who lost their first born female child, also affected by SCID without signs of Fanconi syndrome. The diagnosis of our patient was established from cord blood. The father was heterozygous for ␣-thalassemia (--SEA) and the mother was heterozygous for -thalassemia (IVS1-6 T→C). Hbelectrophoresis of blood from our patient revealed only an ␣-thalassemia trait. He was prepared for stem cell transplantation with antithymocytic globulin 5 mg/kg/day (20 mg/day) for 5 consecutive days because of circulating maternal T cells. He received cyclosporin A to prevent GVHD. On 25 May 1998, he received 80 ml MUD-cord blood without T or B cell depletion, which contained 15.2 ϫ 10 7 NBC/kg body weight. After stem cell transplantation he was treated with methotrexate 2.5 mg/day on days ϩ1 and ϩ3 and cyclosporin A was continued for GVHD prophylaxis. There were no complications during his hospital stay. Unfortunately, no engraftment of T or B cells was documented. He remained in good physical condition with length and weight measurements at the 10th percentile. In December 1998 he received a second stem cell transplant. This time he received bone marrow from a ma...